Therapeutic compositions capable of removing excess nitric oxide are provided. The therapeutic compositions include nitronyl nitroxide monoradicals, B12 derivatives, flavonoid derivatives, the like and combinations thereof. The therapeutic compositions can be utilized in a number of suitable applica
Therapeutic compositions capable of removing excess nitric oxide are provided. The therapeutic compositions include nitronyl nitroxide monoradicals, B12 derivatives, flavonoid derivatives, the like and combinations thereof. The therapeutic compositions can be utilized in a number of suitable applications, such as to prevent or treat intradialytic hypotension during dialysis.
대표청구항▼
1. A method of providing dialysis to a patient, the method comprising: providing a dialysis solution including an osmotic agent and a pharmaceutically active agent comprising a nitronyl nitroxide monoradical selected from the group consisting of 1,3-dihydroxy-2-(2,4-dihydroxyphenyl)-4,4,5,5-tetramet
1. A method of providing dialysis to a patient, the method comprising: providing a dialysis solution including an osmotic agent and a pharmaceutically active agent comprising a nitronyl nitroxide monoradical selected from the group consisting of 1,3-dihydroxy-2-(2,4-dihydroxyphenyl)-4,4,5,5-tetramethylimidazolidine; 1,3-dihydroxy-2-(3,4-dihydroxyphenyl)-4,4,5,5-tetramethylimidazolidine; 1,3-dihydroxy-2-(4-pyridyl)-4,4,5,5-tetramethylimidazolidine; 1,3-dihydroxy-2-(2-thienyl)-4,4,5,5-tetramethylimidazolidine; 1,3-Dihydroxy-2-(2-furyl)-4,4,5,5-tetramethylimidazolidine; and combinations thereof;providing the dialysis solution to the patient; andremoving an excess amount of nitric oxide from the patient effectively without inhibiting synthesis of nitric oxide. 2. The method of claim 1 wherein the composition is administered intravenously to the patient. 3. A method of preventing or treating intradialytic hypotension in a patient undergoing dialysis, the method comprising the steps of: providing a composition to the patient wherein the composition includes a pharmaceutically active agent that includes a nitric oxide scavenger composition; andremoving an excess amount of nitric oxide from the patient effectively without inhibiting synthesis of nitric oxide. 4. The method of claim 3 wherein the nitric oxide scavenger composition is selected from the group consisting of a nitronyl nitroxide monoradical, a B12 derivative, a flavonoid derivative and combinations thereof. 5. The method of claim 4 wherein the nitric oxide scavenger composition is selected from the group consisting of: 1,3-dihydroxy-2-(2,4-dihydroxyphenyl)-4,4,5,5-tetramethylimidazolidine;1,3-dihydroxy-2-(3,4-dihydroxyphenyl)-4,4,5,5-tetramethylimidazolidine;1,3-dihydroxy-2-(4-pyridyl)-4,4,5,5-tetramethylimidazolidine;1,3-dihydroxy-2-(2-thienyl)-4,4,5,5-tetramethylimidazolidine; 1,3-Dihydroxy-2-(2-furyl)-4,4,5,5-tetramethylimidazolidine;hydroxocobalamin; cyanocobalamin; pelargonidin; cyanidin; delphinidin and combinations thereof. 6. The method of claim 3 wherein the composition is administered intravenously to the patient. 7. The method of claim 3 wherein the composition is orally administered to the patient. 8. The method of claim 3 wherein the composition is attached to a semipermeable membrane material within a dialyzer allowing removal of the excess nitric oxide during dialysis. 9. The method of claim 8 wherein the composition is attached to a bead material within a cartridge further allowing removal of the excess nitric oxide during dialysis. 10. A method of providing dialysis to a patient, the method comprising: providing a dialysis solution including an osmotic agent and a pharmaceutically active agent comprising a B12 derivative selected from the group consisting of hydroxocobalamin, cyanocobalamin and combinations thereof;providing the dialysis solution to the patient; andremoving an excess amount of nitric oxide from the patient effectively without inhibiting synthesis of nitric oxide. 11. A method of providing dialysis to a patient, the method comprising: providing a composition including a pharmaceutically active agent comprising a flavonoid derivative selected from the group consisting of pelargonidin, cyanidin, delphinidin and combinations thereof;providing the composition to the patient; andremoving an excess amount of nitric oxide from the patient effectively without inhibiting synthesis of nitric oxide. 12. A method of providing dialysis to a patient, the method comprising: attaching a pharmaceutically active agent to a semipermeable membrane within a dialyzer, the pharmaceutically active agent comprising at least one of i) a nitronyl nitroxide monoradical selected from the group consisting of 1,3-dihydroxy-2-(2,4-dihydroxyphenyl)-4,4,5,5-tetramethylimidazolidine; 1,3-dihydroxy-2-(3,4-dihydroxyphenyl)-4,4,5 ,5-tetramethylimidazolidine; 1,3-dihydroxy-2-(4-pyridyl)-4,4,5,5-tetramethylimidazolidine; 1,3-dihydroxy-2-(2-thienyl)-4,4,5,5-tetramethylimidazolidine; 1,3-Dihydroxy-2-(2-furyl)-4,4,5,5-tetramethylimidazolidine; and combinations thereof, and ii) a B12 derivative selected from the group consisting of hydroxocobalamin, cyanocobalamin and combinations thereof;passing a dialysis fluid through the dialyzer to remove excess nitric oxide from the dialysis fluid; andproviding the dialysis fluid to the patient during dialysis treatment. 13. A method of providing dialysis to a patient, the method comprising: attaching a pharmaceutically active agent to a bead material within a cartridge, the pharmaceutically active agent comprising at least one of i) a nitronyl nitroxide monoradical selected from the group consisting of 1,3-dihydroxy-2-(2,4-dihydroxyphenyl)-4,4,5,5-tetramethylimidazolidine; 1,3-dihydroxy-2-(3,4-dihydroxyphenyl)-4,4,5,5-tetramethylimidazolidine; 1,3-dihydroxy-2-(4-pyridyl)-4,4,5,5-tetramethylimidazolidine; 1,3-dihydroxy-2-(2-thienyl)-4,4,5,5-tetramethylimidazolidine; 1,3-Dihydroxy-2-(2-furyl)-4,4,5,5-tetramethylimidazolidine; and combinations thereof, and ii) a B12 derivative selected from the group consisting of hydroxocobalamin, cyanocobalamin and combinations thereof;passing a dialysis fluid through the cartridge to remove excess nitric oxide from the dialysis fluid; andproviding the dialysis fluid to the patient during dialysis treatment.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (10)
Maeda Hiroshi (Kumamoto JPX) Miyamoto Yoichi (Ibaraki JPX) Akaike Takaaki (Kumamoto JPX), 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide derivatives and their use as therapeutic agents for maintaining b.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.